Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

s was $22.4 million for the quarter ended September 30, 2009 compared to $58.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009 was $26.7 million, or $0.19 per share, compared to $79.0 million, or $0.58 per share, for the same period in 2008.

"The third quarter was one of strong operational and financial results and positions us well for long-term growth," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "We continue to execute on our growth strategy by making progress against our long-term commercial plans, maximizing the potential of our clinical programs and advancing our pipeline."

Third Quarter Highlights

Highlights of Amylin's third quarter and recent activities include:

Corporate

  • Improved non-GAAP operating loss by 64% in the first nine months of 2009 compared to the same period in 2008
  • Entered a Global Development and Commercialization Agreement with Biocon Limited for a novel peptide hybrid
  • Announced Paulo F. Costa as Amylin's Chairman of the Board

Exenatide

  • Received the Day 74 letter from the U.S. Food and Drug Administration (FDA) and submitted the 120 day safety update for exenatide once weekly
  • Presented data from more than 20 studies, with partner Eli Lilly and Company, at the Annual Meeting of the European Association for the Study of Diabetes (EASD). Data presented were the latest research findings on BYETTA and exenatide once weekly

Nine Months Ended September 30, 2009

Total revenues for the nine months ended September 30, 2009 were $614.3 million. This includes net product sales of $569.7 million, including $503.9 million for BYETTA and $65.8 million for SYMLIN. This compares to net product sales of $580.4 million, consisting of $515.9 million for BYETTA and $64.5 million for SYMLIN for the same period in
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 NEWwoodworks, ... , is expanding their brand presence with a website ... over 20 years, NEWwoodworks has specialized in handcrafted cabinetry, ... interior furnishings. NEWwoodworks has earned a reputation for taking ... dare take on. They commonly craft with reclaimed wood, ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
(Date:7/31/2014)... 2014 The VitaSleep FDA cleared ... and provide an easier breathing capacity by slightly adjusting ... that people can breathe easier and helps reduce or ... so that it can meet the needs of each ... often shared by actual customer reviews. Johathan R. ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... 31, 2014 A program for anyone ... to the University of Colorado Anschutz Health and ... loss boot camp and transformation program. , “Extreme ... and Eyeworks USA, is an evidenced-based program inspired by ... by Eyeworks USA. This season, the show has participants ...
Breaking Medicine News(10 mins):Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... Blue branded dental plan,to central Pennsylvania (Lehigh Valley) ... BlueCross announced,today that it is acquiring Dominion Dental ... The move by the region,s,leading health insurer adds ... the Mid-Atlantic Region., "Helping to improve the ...
... Nov. 4 Hospira, Inc.,(NYSE: HSP ), ... announced that Christopher B. Begley, chairman and chief,executive ... Finance,and chief financial officer, will make a formal ... Conference on Wednesday, Nov. 12, 2008, in,Phoenix., ...
... PH ), the global leader in motion ... the purchase of Matrx nitrous oxide,delivery systems from ... to expand its geographic market space for dental ... American base of operations. The,product line will be ...
... Nov. 4 Allied Minds funds research to ... dermal fillers.,Allied Minds, a seed investment firm specializing ... research with Lawrence Berkeley National,Laboratory through creation of ... Eva Turley and Mina Bissell will develop a,technology ...
... of Minnesota Leverages Market Dynamics With New, Plan Offering ... ... NASHVILLE, Tenn., Nov. 4 ,HealthLeaders-InterStudy, a leading provider of managed ... the,national trend of moving from fully insured to self-insured health plans.,According ...
... Sold by A Uniquely-Trained Sales ... ... today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription for ... approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 as ...
Cached Medicine News:Health News:Capital BlueCross Acquires Dominion Dental 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 3Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:Minnesota Employers Buck National Trend and Largely Remain Fully-Insured 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: